Results 211 to 220 of about 43,205 (262)

Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors.

JAMA Netw Open
Turchin A, Petito LC, Hegermiller E, Carnahan R, DeVries A, Goel S, Lansang MC, McDonnell ME, Nair V, Priest E, Willey VJ, Kaul AF, Hernán MA.   +12 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitory Activity of Buckwheat Flour-Derived Peptides and Oral Glucose Tolerance Test of Buckwheat Flour Hydrolysates in Rats. [PDF]

Foods
Mitsui N, Shiono K, Seto Y, Furusho T, Saito C, Takahashi K.   +5 more
europepmc   +1 more source

Risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A nationwide cohort study. [PDF]

Sage Open Chronic Dis
Yeh HY, Lu HF, Lin LY, Chien LN.
europepmc   +1 more source

A Case of Bullous Pemphigoid Triggered by COVID-19 Infection in a Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor. [PDF]

Cureus
Fukata M, Omura T, Maeda K, Mori T, Kato H, Kuzuya M.   +5 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dipeptidyl peptidase-4 inhibitors

Reactions Weekly, 2021
The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire   +2 more sources